← All trials
NCT05839314
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 9, 2023
- Primary completion
- Dec 31, 2025
- Completion date
- Jun 30, 2026
- First posted
- May 3, 2023
- Last posted
- Dec 27, 2023
- Enrollment
- 480
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- People's Liberation Army of ChinaLead sponsor
- Huazhong University of Science and TechnologyCollaborator
- People's Liberation Army of ChinaOverall official - principal investigator
- People's Liberation Army of ChinaReponsible party - principal investigator
- LinkDoc Technology (Beijing) Co. Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.